Ndisang Joseph Fomusi, Lane Nina, Jadhav Ashok
Department of Physiology, University of Saskatchewan College of Medicine, Saskatoon, SK, Canada S7N 5E5.
Am J Physiol Endocrinol Metab. 2009 May;296(5):E1029-41. doi: 10.1152/ajpendo.90241.2008. Epub 2009 Feb 10.
In type 2 diabetes (T2D), postprandial and fasting hyperglycemia are important predictors of cardiovascular diseases; however, few drugs are currently available to simultaneously suppress these conditions. Here, we report an enduring antidiabetic effect of the heme oxygenase (HO) inducer hemin on Goto-Kakizaki rats (GK), a nonobese insulin-resistant T2D model. HO breaks down the heme-moiety-generating antioxidants (biliverdin/bilirubin and ferritin) and carbon monoxide, which stimulate insulin secretion. Hemin induces HO-1 to potentiate HO activity and the HO-derived products. Chronically applied hemin (30 mg/kg ip) for a month reduced and maintained fasting glucose at physiological levels for 3 mo. Before therapy, glucose levels were 9.3 +/- 0.3 mmol/l (n = 14). At 1, 2, and 3 mo posttherapy, we recorded 6.7 +/- 0.13, 5.9 +/- 0.2, and 7.2 +/- 0.2 mmol/l, respectively. Hemin was also effective against postprandial hyperglycemia (14.6 +/- 1.1 vs. 7.5 +/- 0.4 mmol/l; n = 14; P < 0.01), and the effect remained sustained for 3 mo after therapy. The reduction of hyperglycemia was accompanied by enhanced HO-1, HO activity, and cGMP of the soleus muscle, alongside increased plasma bilirubin, ferritin, SOD, total antioxidant capacity, and insulin levels, whereas markers/mediators of oxidative stress like urinary-8-isoprostane and soleus muscle nitrotyrosine, NF-kappaB, and activator protein-1 and -2 were abated. Furthermore, inhibitors of insulin signaling including soleus muscle glycogen synthase kinase-3 and JNK were reduced, while the insulin-sensitizing adipokine, adiponectin, alongside AMPK were increased. Correspondingly, hemin improved glucose tolerance, suppressed insulin intolerance, reduced insulin resistance, and overturned the inability of insulin to enhance glucose transporter 4, a protein required for glucose uptake. Hemin also upregulated HO-1/HO activity and cGMP and lowered glucose in euglycemic Sprague-Dawley control rats albeit less intensely, suggesting greater selectivity of the HO system in diabetic conditions. In conclusion, reduced oxidative stress alongside the concomitant and paradoxical enhancement of insulin secretion and insulin-sensitizing pathways may account for the 3-mo-enduring antidiabetic effect. The synergistic interaction among HO, adiponectin, and GLUT4 may be explored against insulin-resistant diabetes.
在2型糖尿病(T2D)中,餐后和空腹高血糖是心血管疾病的重要预测指标;然而,目前几乎没有药物可同时抑制这些情况。在此,我们报告了血红素加氧酶(HO)诱导剂氯高铁血红素对Goto-Kakizaki大鼠(GK)(一种非肥胖胰岛素抵抗T2D模型)具有持久的抗糖尿病作用。HO分解血红素部分生成抗氧化剂(胆绿素/胆红素和铁蛋白)和一氧化碳,这些物质可刺激胰岛素分泌。氯高铁血红素诱导HO-1以增强HO活性和HO衍生产物。长期给予氯高铁血红素(30 mg/kg腹腔注射)一个月可将空腹血糖降低并维持在生理水平3个月。治疗前,血糖水平为9.3±0.3 mmol/l(n = 14)。治疗后1、2和3个月,我们分别记录到血糖水平为6.7±0.13、5.9±0.2和7.2±0.2 mmol/l。氯高铁血红素对餐后高血糖也有效(14.6±1.1 vs. 7.5±0.4 mmol/l;n = 14;P < 0.01),且治疗后3个月该作用仍持续存在。高血糖的降低伴随着比目鱼肌中HO-1、HO活性和cGMP的增强,同时血浆胆红素、铁蛋白、超氧化物歧化酶、总抗氧化能力和胰岛素水平升高,而氧化应激标志物/介质如尿8-异前列腺素和比目鱼肌硝基酪氨酸、核因子κB以及激活蛋白-1和-2减少。此外,胰岛素信号转导抑制剂包括比目鱼肌糖原合酶激酶-3和JNK减少,而胰岛素增敏脂肪因子脂联素以及AMPK增加。相应地,氯高铁血红素改善了葡萄糖耐量,抑制了胰岛素抵抗,降低了胰岛素抵抗,并扭转了胰岛素无法增强葡萄糖转运蛋白4(一种葡萄糖摄取所需的蛋白质)的能力。氯高铁血红素还上调了HO-1/HO活性和cGMP,并降低了血糖正常的Sprague-Dawley对照大鼠的血糖,尽管作用强度较小,这表明HO系统在糖尿病状态下具有更高的选择性。总之,氧化应激的降低以及胰岛素分泌和胰岛素增敏途径的同时且矛盾的增强可能解释了为期3个月的持久抗糖尿病作用。HO、脂联素和GLUT4之间的协同相互作用可能被用于对抗胰岛素抵抗性糖尿病。